Indeed, CDER Acting Director Michael Davis reinforced the policy point publicly on X, emphasizing that compounded GLP1 products are not FDAapproved and have not undergone the rigorous review for safety, efficacy, and manufacturing quality that is required for drugs approved through the new drug application (NDA) or abbreviated new drug application (ANDA) pathways.[3] This is now the third major set of warning letters in less than a year with the majority aimed at telehealth marketing of compounded GLP-1 products: September 2025: roughly 80 warning letters and 40 untitled letters March 2026: 30 warning letters June 2026: 25 warning letters The Claims FDA Is Targeting As in earlier rounds, the June 2026 letters appear highly standardized and focus on consumerfacing promotion of compounded GLP-1 products
Astaxanthin: Kh nng chng oxy ha gp nhiu ln Vitamin C, gip ngn chn np nhn su
Jantar Sopa de lentilha com pesto de ervas frescas e limo
While semaglutide is the active ingredient in Ozempic, the latter is a branded formulation specifically designed for diabetes treatment
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox
Sermorelin's Role in Recovery and Performance for Men Sermorelin works by prompting your pituitary gland to release more growth hormone
